Oncotarget has over the years risen through the ranks to be a reliable biomedical journal. Since its inception in 2010, the journal has gone a long way into disbursing information in various fields of research such as Pathology, Microbiology among others. With the rise in the prevalence of breast cancer among women, Oncotarget in November 2017 published an invaluable article on Research Gate titled, ‘Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.’ Listen to Oncotarget podcast on Player.FM.
The research is authored by Annelot G.J van Rossum, Marleen Kok, Danielle McCool, Sabine C Linn and more. The research aims to identify the effect of polymorphisms related to the said doses on the toxicity in breast cancer patients. While it is widely accepted that adjuvant chemotherapy enhances survival of breast cancer patient, an understanding of the toxicity would lead to more survival rate in breast cancer patients by reducing cases of relapse.
Mid-September 2017, Oncotarget made an assurance to its readers to continue featuring on PubMed, PubMed Central, BIOSIS Previews, Biological Abstracts and EMBASE among others. This is in line with the journal’s objective of being the first in submitting a whole issue to PubMed shortly after being published online.
To make scientific advances available to experts within the medical circles and to the greater population, Oncotarget has a harmonious working relationship with seasoned scientific indexes and archives. Currently, Oncotarget has published seven volumes with 324 issues therein. Now in its eighth volume, Oncotarget has increased its issues to two every week. The issues will be on PubMed all through after they are assigned their rightful number and are indexed. Issues 31-34 have already been posted on PubMed, and the subsequent issues are on course to appear. Oncotarget research papers are uniquely identified by a direct object identifier (DOI) and adhere to standards of Committee on Publications Ethics (COPE)
Oncotarget uses state of the art submission and manuscript tracking software – https://t.co/LZQlbzuW34
— Oncotarget (@OncotargetJrnl) December 14, 2017
In its words, The Office of External & Legal Affairs of Oncotarget believes to have a life without diseases and therefore making Oncotarget a timely medical journal in the 21st Century. Further, they describe Oncotarget as the journal by scientists for scientists. Learn more about Oncotarget at Research Gate.